By using tumor-transplanted mouse models and xenograft mouse models, we have demonstrated that prophylactic blockade of TNF right before starting the dual anti-PD1 and anti-CTLA-4 therapy prevents irAEs, while maintaining or even enhancing to some extent the therapeutic efficacy of combined ICB therapy (Figure 1D). The gene discussed is TNF; the disease is neoplasm.